Background: Pulmonary tuberculosis (TB), a global health problem, is typically caused by the bacterium Mycobacterium tuberculosis. Herpes zoster (HZ) is caused by the reactivation of the varicella-zoster virus (VZV). The reactivation of VZV can be caused by stress. We investigated whether pulmonary TB increases the risk of HZ development. Methods: This study used data that sampled a population of 2 million people in 2000 from the National Health Insurance Research Database. This cohort study observed Taiwanese patients aged 20–100 years with pulmonary TB from 2000 to 2017 (tracked to 2018). Pulmonary TB was defined as having two or more outpatient diagnoses or at least one admission record. To address potential bias caused by confounding factors, the control cohort and pulmonary TB cohort were matched 1:1 by age, gender, index year, and comorbidities. Patients with HZ before the index date were excluded. Results: A total of 30,805 patients were in the pulmonary TB and control cohorts. The incidence rate of HZ in pulmonary TB and control cohorts were 12.00 and 9.66 per 1000 person-years, respectively. The risk of HZ in the pulmonary TB cohort (adjusted hazard ratios = 1.23; 95% confidence interval = 1.16–1.30) was significantly higher than that of in control cohort. Among patients without comorbidities, the patients with TB were 1.28-fold more likely to have HZ than those without TB. Conclusion: Patients with TB should be well treated to avoid the potential risk of HZ occurrence. Although we identified the association between pulmonary TB and HZ, further studies are needed to confirm the result.
Background: The association between polycystic ovary syndrome (PCOS) and the risk of herpes zoster (HZ) remains unclear. This study investigated the risk of HZ in women with PCOS. Methods: This study used data from the Longitudinal Generation Tracking Database (LGTD 2005) which contains the information of 2 million randomly selected from National Health Insurance beneficiaries. Patients who received a diagnosis of PCOS between 2000 and 2017 were included in the PCOS cohort. Patients who were not diagnosed as having PCOS were randomly selected from the LGTD 2005 and included in the control cohort. Patients who were aged <20 years and had a history of HZ before the index date were excluded. Patients who were in both the cohorts were matched at a ratio of 1:1 through propensity score matching based on age, comorbidities, and medication. The primary outcome was the diagnosis of HZ. Results: A total of 20,142 patients were included in each case and control cohorts. The incidence rates of HZ in the PCOS and control cohorts were 3.92 and 3.17 per 1000 person-years, respectively. The PCOS cohort had a significantly higher risk of HZ than did the control cohort (adjusted hazard ratios [aHR] = 1.26). Among the patients aged 30–39 years, those with PCOS had a significantly higher risk of HZ than did those without PCOS (aHR = 1.31). Among the patients without any comorbidities, those with PCOS had a significantly higher risk of HZ (aHR = 1.26) than did those without PCOS. Conclusion: PCOS is associated with the risk of HZ, especially in young women. The risk of HZ should be addressed while treating patients with PCOS. An HZ vaccine is recommended for these patients.
Background and Objectives: Active pulmonary tuberculosis (aPTB) in the Older Adults (≥75 years) is frequently under-recognized in non-pulmonology settings due to atypical symptoms and multiple comorbidities. This study aimed to develop and validate a TRIPOD-compliant clinical prediction model for early identification of atypical aPTB in this vulnerable population. Materials and Methods: We retrospectively analyzed 5651 patients aged ≥75 years with culture-confirmed aPTB and World Health Organization (WHO) symptom scores < 5. Patients were stratified into Group a (Ga, Patients with aPTB not initially suspected by non-pulmonologists (atypical presentation, WHO/CDC 7-point score < 5, n = 1155) and Group b (Gb, Patients without aPTB within the first 24 h (non-TB comparators), n = 4496). Multivariate logistic regression identified independent predictors of delayed diagnosis. A weighted scoring system was derived from β-coefficients and validated in independent derivation (2000–2020) and temporal validation (2021–2023) cohorts. Model discrimination, calibration, and decision curve analysis (DCA) were assessed following TRIPOD standards. Results: Five independent predictors—age > 85 years (OR = 6.31, 95% CI = 5.31–8.72), hypoalbuminemia (OR = 4.10, 95% CI = 3.92–7.26), cardiovascular disease (OR = 3.32, 95% CI = 1.23–5.27), diabetes mellitus (OR = 2.03, 95% CI = 1.32–4.07), and predominant lower-lung field involvement (OR = 1.25,95% CI = 1.03–2.44)—were incorporated into the scoring model. Using a cutoff ≥ 7, the model achieved excellent performance across all cohorts (AUC 0.95–0.96; sensitivity 91–94%; specificity 97–99%). Calibration plots and DCA confirmed strong agreement and high net clinical benefit. Nearly 70% of atypical cases had symptom scores ≤ 1, lacking typical signs such as fever or cough. Conclusions: Oldest-old (>85 years) emerged as the strongest independent predictor of atypical TB, surpassing conventional frailty indicators such as sarcopenia or osteoporosis. The proposed score provides a simple, accurate, and validated tool for early detection of aPTB in non-pulmonology settings. Its integration into electronic medical records may reduce diagnostic delays and improve outcomes in this high-risk, late-elderly population.